Trump offered german firm cash for u s coronavirus vaccine report

You're referring to a recent news report!

According to a report by The New York Times, President Trump's administration offered a German pharmaceutical company, CureVac, a significant amount of cash to develop a coronavirus vaccine in the United States. The offer was reportedly made in March, when the pandemic was still in its early stages.

CureVac, a biotech company based in Tübingen, Germany, had been working on a vaccine candidate using a new technology that uses a piece of genetic material called messenger RNA (mRNA) to stimulate the immune system. The company had already received funding from the German government and was in the process of conducting clinical trials.

The Trump administration's offer was reportedly worth hundreds of millions of dollars, and would have given the company access to federal resources, including the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). In exchange, CureVac would have had to agree to develop and manufacture the vaccine in the United States, and to make it available to the American public.

However, CureVac ultimately declined the offer, reportedly due to concerns about the company's independence and the potential for political interference in the development of the vaccine. The company also wanted to maintain control over the intellectual property and manufacturing process.

It's worth noting that the Trump administration has been criticized for its handling of the pandemic, including its response to the development of vaccines. The administration has been accused of politicizing the vaccine development process, and of prioritizing its own interests over the needs of the American public.

In any case, the report highlights the complex and often contentious process of developing vaccines, and the challenges that companies and governments face in balancing the need for rapid development with the need for scientific rigor and public trust.